Beta
Back to ABBV.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • Revenue by Segments
  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
operation-income-chart

ABBV Operation Income

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for ABBV's Operation Income in Q4'25 shows a robust $4.54B USD, marking a significant recovery and the highest quarterly figure in the observed period from Q1'23 to Q4'25. This positive outcome contrasts sharply with the previous quarter's Q3'25 dip to $1.90B USD, reflecting improved operational performance in the final quarter of the fiscal year. Over the timeframe from Q1'23 to Q4'25, Operation Income exhibits volatile trends with an overall upward trajectory, fluctuating between a low of -$1.49B USD in Q4'24 and peaks like $4.89B USD in Q2'25, driven by alternating growth and declines across quarters. Year-over-year changes highlight inconsistency, with notable surges such as +404.97% in Q4'25 and +67.95% in Q3'24, alongside sharp drops like -146.64% in Q4'24 and -50.30% in Q3'25, suggesting sensitivity to seasonal or external factors in the pharmaceutical sector. The bar chart visualization underscores these quarterly swings, while the overlaid YoY line indicates improving momentum in recent periods despite earlier instability.